Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation

Keyphrases

• Atrial Fibrillation 100%
• Telmisartan 100%
• Angiotensin II Type 1 Receptor Blocker 100%
• Insulin Sensitizers 100%
• Commercially Available 100%
• Insulin Resistance 40%
• Hypertensive Patients 40%
• Diabetes 30%
• Renin-angiotensin System 30%
• Peroxisome Proliferator-activated Receptor 20%
• Angiotensin-converting Enzyme Inhibitor (ACEi) 20%
• Blood Pressure 10%
• Hypertension 10%
• Beneficial Effects 10%
• Type 1 Diabetes Mellitus (T1DM) 10%
• Gene Expression 10%
• Glucose-insulin System 10%
• Insulin Level 10%
• High Risk 10%
• Attenuation 10%
• Clinical Trials 10%
• Randomized Double-blind 10%
• Weight Gain 10%
• Losartan 10%
• Per Se 10%
• Type I Diabetes 10%
• Hyperglycemia 10%
• Glucose Level 10%
• Community-based 10%
• Triglyceride Level 10%
• Clinical Papers 10%
• Cardiac Rhythm 10%
• Beneficial Role 10%
• Ongoing Clinical Trials 10%
• Partial Agonist 10%
• Carbohydrate Metabolism 10%
• Ramipril 10%
• International multicenter Study 10%
• Common Disorders 10%
• Low-carbohydrate High-fat Diet 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Atrial Fibrillation 100%
• Angiotensin 1 Receptor Antagonist 100%
• Telmisartan 100%
• Insulin 100%
• Insulin Resistance 30%
• Renin 30%
• Angiotensin 30%
• Clinical Trial 20%
• Peroxisome Proliferator Activated Receptor 20%
• Dipeptidyl Carboxypeptidase Inhibitor 20%
• Carbohydrates 20%
• Observational Study 10%
• Hyperglycemia 10%
• Clinical Study 10%
• Losartan 10%
• Insulin Dependent Diabetes Mellitus 10%
• Triacylglycerol 10%
• Morbidity 10%
• Partial Agonist 10%
• Ramipril 10%
• Diseases 10%
• Pathogenesis 10%
• Glucose 10%
• Rat 10%
• Hypertension 10%